GRIFOLS | GRF - Current Liabilities


GRIFOLS reported EUR2.12B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Alcon AG USD 3B 45M Mar/2026
Almirall EUR 350.64M 52.12M Dec/2025
Amadeus IT EUR 3.03B 4.4M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
argenx SE USD 1.32B 278.28M Dec/2025
AstraZeneca USD 32.57B 1.95B Mar/2026
Bayer EUR 33.46B 875M Mar/2026
Cie Automotive EUR 1.92B 8.97M Dec/2025
Demant DKK 7.42B 1.63B Dec/2025
Ence Energia y Celulosa EUR 435.03M 5.93M Dec/2025
Essilor EUR 12.15B 766M Dec/2025
Ferrovial EUR 6.46B 486M Dec/2025
Fresenius EUR 8.38B 1.18B Dec/2025
Fresenius Medical Care EUR 6.73B 484.42M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
GRIFOLS EUR 2.12B 105M Mar/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Inditex EUR 12.47B 2.29B Mar/2026
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Merck EUR 9.35B 307M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Philips EUR 7.43B 78M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Smith & Nephew USD 1.54B 236M Dec/2025
UCB EUR 4.4B 470M Dec/2025
Viscofan EUR 437.49M 43.64M Mar/2026